Short ragweed allergen-specific immunoglobulin G4 (Ragweed-specific IgG4)

Induced allergen-specific IgG and IgG4 against Ambrosia elatior (short ragweed) allergens represent a key immunological biomarker and mechanism of tolerance in allergen immunotherapy (AIT). Ambrosia elatior, commonly known as short ragweed, produces potent allergens such as Amb a 1 that trigger IgE-mediated allergic rhinitis and asthma in sensitized individuals (PMID: 28212950). During AIT, the immune system is repeatedly exposed to these allergens, shifting the immune response from a Th2-driven IgE production toward a Th1 and regulatory T cell (Treg) response characterized by the production of IgG4 (PMID: 21834850). These IgG4 antibodies function as 'blocking antibodies' that intercept allergens before they can bind to IgE on the surface of mast cells and basophils, effectively preventing the allergic cascade (PMID: 19278212). Monitoring the levels of these antibodies is a standard method for assessing the efficacy and immunological shift in patients undergoing treatment for ragweed-induced allergies (PMID: 25617221). While not a therapeutic target in the traditional sense, the induction of these antibodies is the primary pharmacodynamic goal of ragweed desensitization therapies.

Other names

Ambrosia elatior-specific IgG4Ambrosia artemisiifolia-specific IgG4Ragweed-specific IgGBlocking antibodiesInduced allergen-specific IgG/IgG4 against Ambrosia elatior allergens

Allergen immunotherapy (AIT) induces the production of allergen-specific IgG4 antibodies, which act as 'blocking antibodies' by competing with IgE for binding sites on allergens, thereby preventing the cross-linking of IgE on mast cells and basophils and subsequent inflammatory mediator release (PMID: 21834850).